ArticleBritish journal of cancer2012
Analysis of gene alterations of mitochondrial DNA D-loop regions to determine breast cancer clonality.
Article in British journal of cancer, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Genomic and spatial analysis of local recurrences following risk-adapted breast radiotherapy in the IMPORT trials.Breast cancer research : BCR · 2026Article
- Genome-wide analysis of somatic noncoding mutation patterns and mitochondrial heteroplasmic shift in type B1 and B2 thymomas.The Journal of pathology · 2026Article
- Next-generation sequencing of mitochondrial DNA reveals pathogenic variants and protective haplogroup D4 in esophageal cancer.Frontiers in genetics · 2025Article
- ATAD3A: A Key Regulator of Mitochondria-Associated Diseases.International journal of molecular sciences · 2023Review
- Application of Immunohistochemistry in Clinical Practices as a Standardized Assay for Breast Cancer.Acta histochemica et cytochemica · 2023Review
- Phylogenetic analysis of combined lobular and ductal carcinoma of the breast.Molecular medicine reports · 2021Article
- A comprehensive overview of mitochondrial DNA 4977-bp deletion in cancer studies.Oncology reviews · 2019Article
- Contralateral breast cancers: Independent cancers or metastases?International journal of cancer · 2018Article
- Evolution analysis of heterogeneous non-small cell lung carcinoma by ultra-deep sequencing of the mitochondrial genome.Scientific reports · 2017Article
- Mitochondrial DNA sequencing demonstrates clonality of peritoneal implants of borderline ovarian tumors.Molecular cancer · 2017Article
- The Landscape of mtDNA Modifications in Cancer: A Tale of Two Cities.Frontiers in oncology · 2017Review
- Uterine adenosarcomas are mesenchymal neoplasms.The Journal of pathology · 2016Article
- Mitochondrial D310 mutation as clonal marker for solid tumors.Virchows Archiv : an international journal of pathology · 2015Article
- Article
- Small Circular DNAs in Human Pathology.The Malaysian journal of medical sciences : MJMS · 2014Article
- Low copy number of mitochondrial DNA (mtDNA) predicts worse prognosis in early-stage laryngeal cancer patients.Diagnostic pathology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIt has been a challenge to determine breast cancer clonality accurately. The aim of the present study was to assess methods using formalin-fixed paraffin-embedded (FFPE) tissue to differentiate new primary tumours from true recurrences that are associated with poorer prognoses and often require more aggressive treatment.
methodsWe investigated the novel method of analysing gene alterations of mitochondrial DNA D-loop region (GAMDDL) and compared it with the conventional method of analysing the X-chromosome-linked human androgen receptor (HUMARA). The FFPE sections of primary and secondary breast cancers, the non-neoplastic mammary gland, and lymph nodes were examined.
resultsInformative rates for HUMARA, GAMDDL, and combined analyses were 42.1%, 76.9%, and 89.5%, respectively. All of the 10 contralateral breast cancers were determined to be non-clonal. In contrast, 3 out of 8 (37.5%) of the ipsilateral secondary tumours shared a clonal origin with the primary tumour and were classified as true recurrences, whereas 4 out of 8 (50%) were classified as new primary tumours.
conclusionGAMDDL analysis represents a novel and useful molecular method for examining the precise cell lineages of primary and secondary tumours, and was more accurate than HUMARA in determining clonality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.